Patterns of non steroidal anti-inflammatory drug use in ambulatory care;Profil des utilisateurs d'anti-inflammatoires non stéroïdiens

Therapie

Volumn 61, Issue 2, 2006, Pages 109-114

  Lugardon, Stéphanie ^a   Roussel, Henri ^b   Bourrel, Robert ^b   Sciortino, Vincent ^b   Montastruc, Jean Louis ^a   Lapeyre Mestre, Maryse ^a  

^a UNIVERSITÉ DE TOULOUSE   (France)

^b Caisse Nationale d'Assurance Maladie des Travailleurs Salaries   (France)

Author keywords

Coxib; Drug utilization study; Non steroidal anti inflammatory drugs

Indexed keywords

ACETYLSALICYLIC ACID; ALMINOPROFEN; CELECOXIB; DICLOFENAC; ETODOLAC; FENOPROFEN; FLURBIPROFEN; GASTROINTESTINAL AGENT; IBUPROFEN; INDOMETACIN; KETOPROFEN; MEFENAMIC ACID; MELOXICAM; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; NORNIFLUMATE; PIROXICAM; PROSTAGLANDIN SYNTHASE INHIBITOR; ROFECOXIB; SULINDAC; TENOXICAM; TIAPROFENIC ACID; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; AMBULATORY CARE; ARTICLE; DEMOGRAPHY; FRANCE; GASTROINTESTINAL HEMORRHAGE; HEALTH CARE SYSTEM; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; CLASSIFICATION; METHODOLOGY; STATISTICS;

ADULT; AMBULATORY CARE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; FRANCE; HUMANS;

EID: 33748415086     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: 10.2515/therapie:2006029     Document Type: Article

References (17)

1. Commission de la Transparence. Avis de la Commission, 19 mai 2004, 16 juin 2004, Celecoxib CELEBREX. Disponible sur http://afssaps-prd.afssaps.fr/ html/has/sgt/htm/avis/data/ct031568.pdf
2. La Revue Prescrire. Bilan des effets indésirables des coxibs notifiés en France. Rev Prescr 2002; 22: 674
3. Lugardon S, Lapeyre-Mestre M, Montastruc JL. Upper gastrointestinal adverse drug reactions and cyclo-oxygenase-2 inhibitors (celecoxib and rofecoxib): a case/non-case study from the French Pharmacovigilance Database. Eur J Clin Pharmacol 2004; 60: 673-7
4. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastro-intestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343: 1520-8
5. Ray WA, Stein CM, Daugherty JR, et al. COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002; 360: 1071-3
6. Prescrire International. Cardiovascular adverse effects of coxibs. Prescrire Int 2002; 11: 181-2
7. Agence Française de Sécurité Sanitaire des Produits de Santé. Les alertes sanitaires. 30/09/2004 Retrait de tous les lots de VIOXX, comprimé à 12,5 mg et 25 mg - MSD Chibret. Disponible sur http://afssaps-prd.afssaps.fr/html/has/sgt/htm/avis/data/ct031568.pdf
8. CNAMTS. La population protégée par les régimes de sécurité sociale. Dossier Etudes et Statistiques 2003; 56: 12
9. Hernandez-Diaz S, Rodriguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastro-intestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000; 160: 2093-9
10. Wolfe F, Flowers N, Burke TA, et al. Increase in lifetime adverse drug reactions, service utilization, and disease severity among patients who will start COX-2 specific inhibitors: quantitative assessment of channeling bias and confounding by indication in 6689 patients with rheumatoid arthritis and osteoarthritis. J Rheumatol 2002; 29: 1015-22
11. MacDonald TM, Morant SV, Goldstein JL, et al. Channelling bias and the incidence of gastro-intestinal haemorrhage in users of meloxicam, coxibs, and older, non-specific non-steroidal anti-inflammatory drugs. Gut 2003; 52: 1265-70
12. Laine L, Wogen J, Yu H. Gastrointestinal health care resource utilization with chronic use of COX-2-specific inhibitors versus traditional NSAIDs. Gastroenterology 2003; 125: 389-95
13. Layton D, Hughes K, Harris S, et al. Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed celecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data. Rheumatology (Oxford) 2003; 42: 1332-41
14. Moride Y, Ducruet T, Boivin JF, et al. Prescription channelling of COX-2 inhibitors and traditional nonselective anti-inflammatory drugs: a population-based case-control study. Arthritis Res Ther 2005; 7: R333-42
15. Wolfe F, Anderson J, Burke TA, et al. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy. J Rheumatol 2002; 29: 467-73
16. CNAMTS. Pour mieux comprendre la statistique mensuelle en date de soins. Points de conjoncture, Note méthodologique, 2002, Disponible sur http://www.ameli.cnamts.fr/157/DOC/621/article_pdf.html
17. Marquaille V, Rempp R, Dechamp C, et al. Celecoxib : étude des motifs de prescription en soins de ville au regard des indications thérapeutiques officielles. Revue Médicale de l'Assurance Maladie 2003; 34: 167-73